Market Luther Kang

Deep dives into small biotech stocks. Helping you find alpha before the 10-K hits. 📈

[Market Luther Kang @awisejester]

@RyanRynoT Glad I bought the dip. Looking forward to what's coming

[Market Luther Kang @awisejester]

@RyanRynoT Thanks for that correction. Tuesday.
And I'm fine with the lower price from a shakeout. My plan was to always hold in anticipation for Q3 anyways. I get to average down now

[Market Luther Kang @awisejester]

$SLN The "digital smoke" is getting thick. 🕵️‍♂️ Just audited the IR server (q4cdn) and we’ve got a massive technical shift. The /2026/ directory just flipped from a 403 Forbidden to a 302 Redirect. 1/x

[Market Luther Kang @awisejester]

@RyanRynoT No clue. Price today's terrible. The only day that makes sense is Monday. If nothing happens then, I think we'll be forced to wait until Q3.

[Market Luther Kang @awisejester]

@RyanRynoT 😂

[Market Luther Kang @awisejester]

@RyanRynoT For sure. Tomorrow's the last day so I'm hoping we get the news then but things could still be getting negotiated and if so, we'll have to be patient but I'm really hoping what we're seeing means we won't wait long for it.

[Market Luther Kang @awisejester]

@RyanRynoT Under the UK Takeover Code, if a company is in an "offer period," they are legally required to have a dedicated section on their website for all documents related to the offer. The sudden appearance (and then "hiding") of this path is a strong indicator of tactical preparation.

[Market Luther Kang @awisejester]

@RyanRynoT The sitemap instructions were tightened on January 7, 2026. This move effectively "hid" the newly created /investors/offer/ and /transaction-details/ folders from public search engines just 48 hours before the JPM conference.

[Market Luther Kang @awisejester]

@RyanRynoT I used Gemini to find out - used crawlers in the background to find the hidden data. Check it out and see if you get the same outcome

[Market Luther Kang @awisejester]

@RyanRynoT That's what I'm thinking

[Market Luther Kang @awisejester]

@type You don't "embargo" a routine presentation. You embargo a Merger Announcement. Don't forget the Jan 6th Form 4s—the entire board (Ross, Hellums, etc.) converted their options to common shares 8 days ago. They cleaned the cap table for a reason. 3/x

[Market Luther Kang @awisejester]

A 302 redirect means the content is STAGED and LIVE on the backend, but they are temporarily routing traffic away until the exact "Go-Live" timestamp. Combine that with the new https://t.co/qGXXQOZRGr "@type: Event" tags that just hit the header code for Jan 14th. 2/x

[Market Luther Kang @awisejester]

@RyanRynoT Maybe post market or tomorrow we'll hear something

[Market Luther Kang @awisejester]

$SLN The administrative trail for Silence Therapeutics has shifted from routine partnership to a definitive buyout signature. It started on December 1 when AstraZeneca management met with Rothschild in London to lock the valuation models. 1/x

[Market Luther Kang @awisejester]

@RyanRynoT Good price action reversal today so let's hope we're able to get you in the money before then

[Market Luther Kang @awisejester]

@RyanRynoT It's undervalued. Great platform pumping out two basically best in class products with potential for more. Plus ironclad patents since they went up against alnylam and won. Only shares on my end. When do your options expire?

[Market Luther Kang @awisejester]

@RyanRynoT Anything is possible. Just have to wait and see at this point.

[Market Luther Kang @awisejester]

@RyanRynoT Guess it didn't pan out for us. Q3 it is

[Market Luther Kang @awisejester]

@RyanRynoT I did. I think you may be right Ryan. Let's see how it goes tomorrow!

[Market Luther Kang @awisejester]

@RyanRynoT Did some additional digging and you may be on to something about a buyout on Monday. Fingers crossed it happens

[Market Luther Kang @awisejester]

$SLN The Stereogenic Moat: Better than Arrowhead. Silence’s mRNAi GOLD platform focuses on reducing undefined stereogenic centers in the siRNA molecule. Most siRNA is a messy mixture of slightly different molecules. Silence has figured out how to make their drug structurally pure